• ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Search
EUCAST
menu
Back Close
  • About EUCAST
    About EUCAST
    • Overview
    Close
    Organisation
    • Overview
    • Steering Committee
    • General Committee
    • EUCAST Statutes
    • National AST Committees (NAC)
    • Network Laboratories
    • Development Laboratories (EDL)
    • View all
    Subcommittees
    • Overview
    • Antimycobacterial Susceptibility Testing (AMST)
    • Antifungal Susceptibility Testing (AFST)
    • Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST)
    • Phage Susceptibility Testing Subcommittee (PST)
    • Subcommittee on WGS and Phenotypic AST
    • View all
    Meetings
    • Overview
    • Steering Committee Meetings
    • General Committee Meetings
    Public Consultations
    • Overview
    SOPs
    • Overview
    IVDR and EUCAST
    • Overview
    News
    • Overview
    Publications and Presentations
    • Overview
  • Bacteria
    Bacteria
    • Overview
    Close
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical Breakpoint Tables
    • Definition of S, I and R
    • When there are no breakpoints?
    • Breakpoints in Brackets
    Guidance Documents
    • Overview
    Important Additional Information
    • Overview
    • Expert Rules
    • Expected Phenotypes
    • Resistance Detection
    MIC and Zone Distributions, ECOFFs
    • Overview
    Methodology and Instructions
    • Overview
    • Disk Diffusion and Quality Control
    • MIC Determination
    • Warnings
    • Media Preparation
    • Disk Diffusion Implementation
    • EUCAST Panels of Phenotypically Defined Strains
      • Overview
      • EUCAST Panel of S. pneumoniae and betalactam agents
      • EUCAST Panel of nine well characterized P. aeruginosa strains
    • IVDR and EUCAST
    • View all
    Rapid AST in blood culture
    • Overview
    • Rapid AST directly from blood culture bottles
    • Methods and Quality Control
    • Breakpoints for Rapid AST
    • Resistance Detection in RAST
    • RAST FAQ
    • RAST MIC:zone diameter correlations
    • RAST Publications
    • View all
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • About Clinical Breakpoints
    • Setting Breakpoints
    • Public Consultations
    • Rationale Documents
    • MIC:Zone Diameter correlations
    • Technical Notes on Antibacterial Agents
    • View all
    FAQ and EDL Services
    • Overview
    • FAQ
    • EDL MIC Testing Services
  • Mycobacteria (AMST)
    Mycobacteria (AMST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of Clinical Breakpoints and ECOFFs
    • Overview
    • Public Consultations
    • Rationale Documents
    Methodology and Instructions
    • Overview
    • Reference Method
    • Mycobacteria FAQ
    • Warnings
    • IVDR and EUCAST
    Publications and Presentations
    • Overview
  • Fungi (AFST)
    Fungi (AFST)
    • Overview
    Close
    Subcommittee
    • Overview
    Clinical Breakpoints and Interpretation
    • Overview
    • Clinical breakpoint table
    • When there are no antifungal breakpoints
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale documents
    • Public consultations
    Methodology and Instructions
    • Overview
    • AST of Yeasts
    • AST of Moulds
    • AST of Dermatophytes
    • Warnings
    • Quality Control
    • IVDR and EUCAST
    • View all
    Publications and Presentations
    • Overview
    • Technical Notes on Antifungal Agents
  • VetCAST
    VetCAST
    • Overview
    Close
    Subcommittee
    • Overview
    MIC distributions and ECOFFs
    • Overview
    Development of clinical breakpoints and ECOFFs
    • Overview
    • Rationale Documents
    Publications and presentations
    • Overview
  • Industry
    Industry
    • Overview
    Close
  • Education
    Education
    • Overview
    Close
Search
  • ESCMID
  • CMI
  • EUCAST Newsletter
  • EUCAST News
Frequent searches
  • breakpoints
  • rationale documents
  • expected phenotypes
  • public consultation
  • endocarditis pathogens
  • guidance documents
Suggestions
  1. Home
  2. Search

Search Results

General

Bacteria

Bacteria Most of EUCAST’s work is dedicated to defining breakpoints for bacteria that cause infections in humans. How to Use This Section: This page gives you access to information and services related to pathogenic bacteria. Important: All resources here are complementary. Please review them…

Get to know more

The farewell of an old webmaster

Within days the EUCAST website will have a new face. Do not worry - you do not have to prepare, change or add anything. The old webmaster bows out and someone new takes over. I have looked after the website and its transitions for exactly 25 years but have no hand in the most recent transition. I am…

Get to know more

A revised version of the guidance on "What to do when there are no breakpoints" published

Following frequent questions and pleas for further guidance, EUCAST has revised the document " What to do when there are no breakpoints ". This is not the type of document where a consultation is part of the process. However, it is important that colleagues understand and agree with the advice…

Get to know more

Breakpoints in brackets

EUCAST introduced breakpoints in brackets in 2020. In breakpoint table 12.0 (2022) there are breakpoints in brackets for aminoglycosides, colistin and for clindamycin for Bacteroides spp. A guidance document describes how to interpret and report breakpoints in brackets.

Get to know more

Industry

Information for pharmaceutical companies intending to bring new antimicrobial drugs to EUCAST for breakpoints The development of clinical breakpoints for new agents requires agreement and acceptance of the data generated in support of decisions on clinical breakpoints, wild type MIC distributions,…

Get to know more

What to do when there are no breakpoints?

What to do when there are no breakpoints? Not every agent and/or species have breakpoints in EUCAST breakpoint tables. For some there may be PK/PD breakpoints, for others MIC distributions to guide recommendations. In this guidance document EUCAST gives advice on how to deal with uncommon species or…

Get to know more

When there are no breakpoints?

When there are no breakpoints? When there are no breakpoints? Guidance document, 29 September 2024 Download PDF Sometimes breakpoints for a species and/or an agent are lacking in EUCAST tables. This may happen because data to allow setting breakpoints is lacking, especially for rare species;…

Get to know more

Disk Diffusion and Quality Control

Disk Diffusion and Quality Control EUCAST have developed standardised disk diffusion methods for both aerobic and anaerobic bacteria. EUCAST antimicrobial susceptibility testing is performed with phenotypic methods, reference broth microdilution or standardised disk diffusion. The basis of all…

Get to know more

Resistance Detection

Resistance Detection Successful treatment of infectious diseases relies on knowledge and understanding of when antimicrobial resistance is an expected phenotype of the organism, and when resistance to antimicrobial agents may develop. The following documents provide up-to-date advice on how to…

Get to know more

Legionella AST - guidance updated

The EUCAST guidance document on susceptibility testing on L.pneumophila isupdated. Acquired antimicrobial resistance in L. pneumophila is rare [1-6]. However, a clinical isolate resistant to ciprofloxacin due to a single point mutation in the gyrA gene has been reported [7] and fluoroquinolone…

Get to know more
Show more results
© EUCAST 2025. All rights reserved EUCAST.
ContactSitemapPrivacy NoticeDisclaimerCookies

Welcome to the new EUCAST website!

We’ve prepared a short video to help you get familiar with the new layout and features.

Watch the video here